Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 184Carcinoma, Non-Small-Cell Lung 143Multiple Myeloma 118Prostatic Neoplasms 116Leukemia, Myeloid, Acute 75Colorectal Neoplasms 75Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 65Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 63Pancreatic Neoplasms 55Ovarian Neoplasms 49Sarcoma 45Carcinoma, Renal Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Advanced Rare Malignant Solid Neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡